Lykan And Vineti Form Cell Therapy Agreement – Contract Pharma

Lykan Bioscience, a contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, which offers a software platform supporting supply chain orchestration for clinical and commercial cell therapies, have entered a partnership to unite Lykans purpose-built cell therapy manufacturing capabilities and Vinetis supply chain and data management system. The partnership empowers biopharma customers with optimized manufacturing efficiency and a complete solution to bring cell-based, life-saving therapies to patients in need.Advanced therapies, such as cell therapies, require advanced infrastructure. Legacy systems managing the production of cell therapies are often manual and outdated, slowing the scale, speed, and patient safety during development. The cell therapy industry requires a new level of visibility, detail, and access across each product and facility within the supply chain. Lykan and Vinetis global, non-exclusive partnership between two leading innovators in the cell therapy space will ensure chain of identity (COI) and chain of custody (COC) visibility as therapies go through each step in the manufacturing supply chain, bringing patient safety back to the forefront.At Lykan, our mission is to be an innovative manufacturer of cell therapy products. We strive to help our biopharma partners achieve a rapid transition from clinical to commercial manufacturing and maximize patient access to cell therapies. The complex nature of cell therapy process development and manufacturing means our partners need innovative technologies, a reliable platform and strong manufacturing expertise to deliver safe and effective therapies, said Patrick Lucy, president and CEO, Lykan. Our strategic partnership with Vineti aims to enable our partners success with faster and simpler operations using a more robust and traceable control system.Lykan Bioscience has established a world-class, purpose-built, multi-product cell therapy manufacturing facility just outside of Boston, MA. Advanced and integrated software systems, such as Vinetis Personalized Therapy Management (PTM) platform, a proven purpose-built, enterprise-grade digital solution for advanced therapy data and supply chains, will enable Lykan to conduct real-time monitoring of the manufacturing process and product, complete with electronic batch records that will support real-time testing and release of product from each of Lykans eight clinical and commercial cGMP manufacturing suites.Amy DuRoss, CEO of Vineti, said, Cell therapies are at a point where they require a truly world-class, purpose-built, multi-product cell therapy manufacturing facility, with the best digital tools, allowing for true connectivity across the ecosystem. We are thrilled to partner with Lykan Bioscience to ensure COI and COC visibility as therapies go through each step in the supply chain, to efficiently deliver these therapies to the patients that need them faster."This partnership follows Lykans recent announcement on the hiring of the companys new CTO and Vinetis release of its PTM Essentials solution for clinical-phase advanced therapies. More information on the Lykan-Vineti solution is available through both companys business development teams.

More:
Lykan And Vineti Form Cell Therapy Agreement - Contract Pharma